Fund Houses Recommendations: TCS, FEDRALBANK, BHARTIHEXA, ZOMATO, PRESTIGE, ABB, PHARMASTOCKS, VEDANTA
અમદાવાદ, 12 જુલાઇઃ અગ્રણી બ્રોકરેજ હાઉસ તથા ફંડ હાઉસ દ્વારા પસંદગીના સ્ટોક્સમાં ખરીદી/ વેચાણ/ હોલ્ડ કરવા માટે સલાહ આપવામાં આવી છે તે રોકાણકારોના અભ્યાસ માટે અત્રે રજૂ કરીએ છીએ.
Jefferies on TCS: Upgrade to Buy on Company, raise target price at Rs 4615 from Rs 4030 (Positive)
UBS on TCS: Maintain Buy on Company, target price at Rs 4600 (Positive)
Nuvama on TCS: Maintain Buy on Company, raise target price at Rs 4800 (Positive)
JP Morgan on TCS: Maintain Overweight on Company, raise target price at Rs 4600 (Positive)
MS on Prestige: Maintain Overweight on Company, target price at Rs 1770 (Positive)
UBS on Federal Bank: Upgrade to Buy on Bank, raise target price at Rs 250 (Positive)
UBS on Zomato: Maintain Buy on Company, raise target price at Rs 260 (Positive)
Investec on Bharti Hexa: Initiate Buy on Company, target price at Rs 1240 (Positive)
Investec on Bharti Airtel: Maintain Hold on Company, raise target price at Rs 1560 (Positive)
Nomura on Indian Budget: Expect a cut to the FY25 fiscal deficit target (Positive)
Jefferies on Pharma Sector: Key Takeaways from IQVIA US data for May & June-24. Sun Pharma, Biocon and Zydus shows strong performance (Positive)
Citi on TCS: Maintain Sell on Company, target price at Rs 3645 (Positive)
Nomura on TCS: Maintain Neutral on Company, raise target price at Rs 3860 (Neutral)
CLSA on TCS: Maintain Buy on Company, raise target price at Rs 4007 (Neutral)
UBS on ABB: Downgrade to Neutral on Company, raise target price at Rs 9100 (Neutral)
Axis on Vedant Fashion: Downgrade to Add on Company, cut target price at Rs 1150 (Negative)
(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)
(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ #ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)
